Amexdrug Corporation (AXRX)
Commerce, CA, US
Amexdrug Corporation, founded in 1963 and headquartered in Commerce, California, operates as a pharmaceutical and cosmeceutical enterprise. Primarily, the company, via its subsidiaries, distributes pharmaceutical products. Beyond this core function, Amexdrug is also deeply involved in the entire lifecycle of pharmaceutical drugs, cosmetics, and medical devices, from their research and development phases through manufacturing and ultimate sale. The company's operations are divided into two main divisions: Distribution and Health and Beauty Products. Its extensive distribution network encompasses a wide range of items, including prescription and over-the-counter medications, various non-drug products, and health and beauty essentials. Amexdrug also provides services in private manufacturing and labeling. Specific product lines manufactured and sold by the company, often under its Sponix brand, include facial and body creams, arthritic pain relief treatments, and hair and nail care products. These goods are supplied to a diverse clientele such as pharmacies, beauty salons, beauty supply outlets, and other retail establishments. Within the state of California, Amexdrug's distribution channels primarily target independent pharmacies, extending secondarily to smaller pharmacy chains, alternative care facilities, and various wholesalers and retailers. The company adopted the name Amexdrug Corporation in April 2000, changing from its previous identity as Harlyn Products, Inc., to reflect its strategic focus on pharmaceutical sales.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -92.00% | -99.82% | -99.71% | -99.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-14.6% Q1'26: -8.4% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q1'26: +150.0% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.4% ★ Q1'26: +0.0% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.7% Q1'26: +6.4% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+25.7% ★ Q1'26: +33.1% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.15× ★ Q1'26: 2.23× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jack Amin | Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief Accounting Officer, Secretary & Treasurer | 154.8K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AXRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
